Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial.
Glesby, Marshall J
Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial. [electronic resource] - PloS one 2013 - e61160 p. digital
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
1932-6203
10.1371/journal.pone.0061160 doi
Abdominal Fat--drug effects
Blood Glucose--metabolism
Body Composition--drug effects
Double-Blind Method
Female
Glucose Tolerance Test
HIV Infections--drug therapy
Homeostasis
Human Growth Hormone--adverse effects
Humans
Insulin Resistance
Insulin-Like Growth Factor I--metabolism
Lipid Metabolism--drug effects
Male
Middle Aged
Placebos
Recombinant Proteins--pharmacology
Rosiglitazone
Thiazolidinediones--adverse effects
Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial. [electronic resource] - PloS one 2013 - e61160 p. digital
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
1932-6203
10.1371/journal.pone.0061160 doi
Abdominal Fat--drug effects
Blood Glucose--metabolism
Body Composition--drug effects
Double-Blind Method
Female
Glucose Tolerance Test
HIV Infections--drug therapy
Homeostasis
Human Growth Hormone--adverse effects
Humans
Insulin Resistance
Insulin-Like Growth Factor I--metabolism
Lipid Metabolism--drug effects
Male
Middle Aged
Placebos
Recombinant Proteins--pharmacology
Rosiglitazone
Thiazolidinediones--adverse effects